Literature DB >> 8823354

Pharmacoeconomics of antipsychotic drug therapy.

W A Hargreaves1, M Shumway.   

Abstract

Treatment cost can have a dramatic effect on treatment availability, and clinicians may find themselves unable to provide expensive treatments they believe their patients should receive. The introduction of new, premium-priced antipsychotic medications has provided visible examples of this problem. Cost considerations must be part of treatment decisions, since resources are often insufficient to provide all potentially helpful treatments. However, the key question regarding expensive drugs is whether other savings can be expected to offset the higher drug price, or if not, whether improved effectiveness justifies the added cost. Pharmacoeconomic research attempts to integrate relevant information on both effectiveness and cost so that clinicians, patients, and other decision-makers can make meaningful treatment choices. This article presents a conceptual framework for cost-effectiveness analysis, illustrates pharmacoeconomic methods with studies of the cost-effectiveness of clozapine treatment, and describes the steps in designing cost-effectiveness research on novel antipsychotic agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823354

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 2.  Methods for claims-based pharmacoeconomic studies in psychosis.

Authors:  Frank Gianfrancesco; Ruey-Hua Wang; Ramy Mahmoud; Richard White
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Authors:  S H Hamilton; D A Revicki; E T Edgell; L A Genduso; G Tollefson
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 4.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

Review 5.  Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.

Authors:  William A Hargreaves; P Joseph Gibson; Joseph P Gibson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Authors:  E T Edgell; S W Andersen; B M Johnstone; B Dulisse; D Revicki; A Breier
Journal:  Pharmacoeconomics       Date:  2000-12       Impact factor: 4.981

Review 7.  Impact of atypical antipsychotics on quality of life in patients with schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Assessing health utilities in schizophrenia. A feasibility study.

Authors:  L N Voruganti; A G Awad; L K Oyewumi; L Cortese; S Zirul; R Dhawan
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

9.  Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia.

Authors:  Tatiana Dilla; Antonio Ciudad; María Alvarez
Journal:  Patient Prefer Adherence       Date:  2013-04-04       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.